Association of asymptomatic hyperuricemia and endothelial dysfunction in psoriatic arthritis

Egyptian Rheumatologist

Volumn 34, Issue 2, 2012, Pages 83-89

  Ibrahim, Soha Eldessouki ^a   Helmi, Amir ^a   Yousef, Tarek M ^a   Hassan, Mohammad Sobhi ^a   Farouk, Naglaa ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Atherosclerosis; Endothelial dysfunction; Hyperuricemia; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; URIC ACID;

ADULT; AGE DISTRIBUTION; ARTERIAL WALL THICKNESS; ARTICLE; ASYMPTOMATIC DISEASE; B SCAN; BRACHIAL ARTERY; BRACHIAL FLOW MEDIATED DILATATION; CAROTID ARTERY FLOW; CAROTID ATHEROSCLEROSIS; CLINICAL ASSESSMENT; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS AREA SEVERITY INDEX; PSORIATIC ARTHRITIS; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

EID: 84880395863     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2012.03.002     Document Type: Article

References (34)

1. Peters M.J., Van der Horst-Bruinsma I.E., Dijkmans B.A., Nurmohamed M.T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004, 34:585-592.
2. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
3. Gonzaley-Juanatey C., Llorca J., Amigo-Diaz E., Dierssen T., Martin J., Gonzaley-Gay M.A. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:1074-1080.
4. Brunner H., Cockcroft J.R., Deanfield J., Donald A., Ferrannini E., Halcox J., et al. Endothelial function and dysfunction. Part II. Association with cardiovascular risk factors and diseases: a statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233-246.
5. Karadag A.S., Yavuz B., Ertugrul D.T., Akin K.O., Yalcin A.A., Deveci O.N., et al. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 2010, 49:642-646.
6. Neunteufl T., Heher S., Katzenchlager R., Wölfl G., Kostner K., Maurer G., et al. Late prognostic value of flow-mediated dilatation in the brachial artery of patients with chest pain. Am J Cardiol 2000, 86:207-210.
7. Usta M., Yurdakul S., Aral H., Turan E., Oner E., Inal B.B., et al. Vascular endothelial function assessed by a noninvasive ultrasound method and serum asymmetric dimethylarginine concentrations in mild-to-moderate plaque-type psoriatic patients. Clin Biochem 2011, 44:1080-1084.
8. Wallberg-Jonson S., Ohman M.L., Rantapää Dahlquist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Primary prevention in rheumatology: the importance of hyperuricemia. Scand J Rheumatol 2004, 33:373-379.
9. Vázquez-Mellado J., Alvarez Hernández E., Burgos-Vargas R. Primary prevention in rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheumatol 2004, 18:111-124.
10. Moll J.M., Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3(1):55-78.
11. Wikipedia. Psoriasis area severity index. http://www.Answers.com/topic/Psoriasis-area-severity-index.
12. Prevoo M.L., vańt Hof M.A., Kuper H.H., vanLeeuween M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
13. Garrett S., Jenkinson T., Kennedy L.G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
14. Correti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
15. Tam L., Shang Q., Li E., Tomlinson B., Chu T., Li M., et al. Subclinical atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008, 59:1322-1331.
16. Eder L., Zisman D., Barzilai M., Laor A., Rahat M., Rozenbaum M., et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008, 35:877-882.
17. Gonzaley-Juanatey Llorca J., Miranda-Filloy J.A., Amigo-Diaz E., Testa A., Garcia-Porrua C., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293.
18. Ramonda R., Lo Nigro A., Modesti V., Nalotto L., Musacchio E., Iaccarino L., et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011, 10:773-778.
19. Klocke R., Cockcroft J.R., Taylor G.I., Hall I.R., Blake D.R. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003, 62:414-418.
20. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963. [review].
21. Kimhi O., Caspi D., Bornstein N.M., Maharshak N., Gur A., Arbel Y., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36:203-209.
22. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8:538-542.
23. Bassi N., Ghirardello A., Iaccarino L., Zampieri S., Rampudda M.E., Atzeni F., et al. OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 2007, 7:52-58.
24. Galkina E., Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2292-2301.
25. Glowinska B., Urban M., Peczynska J., Florys B. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 2005, 54:1020-1026.
26. Van Doornum S., McColl G., Jenkins A., Green D.J., Wicks I.P. Screening for atherosclerosis in patients with rheumatoid arthritis: Comparison of two in vivo tests of vascular function. Arthritis Rheum 2003, 48:72-80.
27. Mehlis S.L., Gordon K.B. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003, 49:S44-S50.
28. Sitia S., Tomasoni L., Atzeni F., Ambrosio G., Cordiano C., Catapano A., et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9:830-834.
29. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Gomez-Acebo I., Miranda-Filloy J.A., Paz-Carreira J., et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009, 39:157-162.
30. Contessa C., Ramonda R., Lo Nigro A., Modesti V., Lorenzin M., Puato M., et al. Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data. Reumatismo 2009, 25:298-305.
31. Sattar N., McCarey D.W., Capell H., McInnes I.B. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293.
32. Ruggiero C., Cherubini A., Miller E., Maggio M., Najjar S.S., Lauretani F., et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol 2007, 100:115-121.
33. Nieto F.J., Iribarren C., Gross M.D., Cosmotock G.W., Culter R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
34. Tomiyama H., Higashi Y., Takase B., Node K., Sata M., Inoue T., et al. Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am J Hypertens 2011, 24:770-774.